Siepmann J, Siepmann F
This article should serve as a guide, but it's not a substitute for professional medical advice.
That is the whole point
Most research applications utilize the following framework: Initial Research Phase: Total blend concentration: 12mg per vial Reconstitution volume: 2-3mL bacteriostatic water Research dosage range: 100-300mcg per administration Frequency: 1-2 times daily during active research periods Advanced Research Protocols: tesa component : 50-100mcg per dose CJC1295 component : 100-200mcg per dose Ipamorelin component : 100-300mcg per dose Combined cjc1295 ipamorelin dosage : 200-500mcg total The tesa cjc1295 ipamorelin 12mg blend reconstitution process requires precise measurement and sterile technique to maintain research integrity
Commercial, HMO, POS, EPO and PPO Plans (Charter, Choice,Core, Doctors Plan, Freedon, Heritage, Navigate, Nexus ACO, Options PPO, Passport Connect, Select) Indemnity Medicare Advantage (AARP, Care Improvement Plus, C-SNP, D-SNP, I-SNP, Erickson Advantage, ERS Medicare Advantage, TRS-Care Medicare Advantage, UnitedHealthcare Chronic Complete, UnitedHealthcare Connected (Medicare-Medicaid Plan), UnitedHealthcare Dual Complete, UnitedHealthcare Group Medicare Advantage PPO, United Healthcare Medicare Complete) Community Plans* (CHIP, CHIP Perinate, Star, Star Kids, Star Plus, MMP) Wellmed (Wellmed Dual SNP Focus, Wellmed Medicare Advantage Focus) *Some providers may not accept Wellpoint, please call to confirm
Cell 135 , 907918 (2008)
)
